CLSD

AcronymDefinition
CLSDClosed
CLSDCornwall-Lebanon School District (Lebanon, Pennsylvania)
CLSDCertified Lodging Security Director (American Hotel & Motel Association)
CLSDCommunity Learning and Skills Development (UK)
CLSDCraniolenticulosutural Dysplasia
CLSDClay, Some Sand (lithological term)
CLSDColor Large Screen Display
CLSDClutch Limited Slip Differential
References in periodicals archive ?
However, no significant effects on CLSD infection were obtained.
Clearside Biomedical Inc (NASDAQ: CLSD) shares -- which came under intense selling pressure in late August after the company hinted at a possible FDA rejection of the NDA for its macular edema drug -- got a reprieve Wednesday.
(NASDAQ: CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that Thomas A.
Clearside Biomedical (CLSD), down 48% after announcing it will discontinue development of combination therapy for RVO.
Clearside Biomedical, Inc.(NASDAQ: CLSD) shares were also up, gaining 53% to $0.8950 after the company announced an option and license agreement for exclusive worldwide rights to its SCS Microinjector with REGENXBIO.
(NASDAQ: CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that its second quarter 2019 financial results will be reported on Wednesday, August 7, 2019.
Among the notable losers was Clearside Biomedical (CLSD), which slid 25% after reporting results from its Phase 2 clinical trial of CLS-TA.
Clearside Biomedical, Inc.(NASDAQ: CLSD) shares were also up, gaining 29% to $0.7575 after the company announced an option and license agreement for exclusive worldwide rights to its SCS Microinjector with REGENXBIO.
(NASDAQ: CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that multiple oral presentations were delivered on Clearside's pipeline and proprietary SCS Microinjector targeting the suprachoroidal space (SCS) at the American Society of Retinal Specialists (ASRS) Annual Meeting.
Also higher was Clearside Biomedical (CLSD), which rose 40% after CLS-TA demonstrated statistically significant efficacy on both primary and secondary endpoints in a Phase 3 trial in non-infectious uveitis patients.
* Clearside Biomedical, Inc.(NASDAQ: CLSD) rose 40.2% to $0.8212 after the company announced an option and license agreement for exclusive worldwide rights to its SCS Microinjector with REGENXBIO.
Also higher was Clearside Biomedical (CLSD), which surged 32% after CLS-TA demonstrated statistically significant efficacy on both primary and secondary endpoints in a Phase 3 trial in non-infectious uveitis patients.